Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Interdisciplinary multimodality management of stage III nonsmall cell lung cancer.

Huber RM, De Ruysscher D, Hoffmann H, Reu S, Tufman A.

Eur Respir Rev. 2019 Jul 8;28(152). pii: 190024. doi: 10.1183/16000617.0024-2019. Print 2019 Jun 30. Review.

2.

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.

Peters S, Felip E, Dafni U, Belka C, Guckenberger M, Irigoyen A, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Tufman A, Lambrecht M, Andratschke N, Piguet AC, Kassapian M, Roschitzki-Voser H, Rabaglio-Poretti M, Stahel RA, Vansteenkiste J, De Ruysscher D.

Lung Cancer. 2019 Jul;133:83-87. doi: 10.1016/j.lungcan.2019.05.001. Epub 2019 May 3.

PMID:
31200833
3.

"Age matters"-German claims data indicate disparities in lung cancer care between elderly and young patients.

Walter J, Tufman A, Holle R, Schwarzkopf L.

PLoS One. 2019 Jun 12;14(6):e0217434. doi: 10.1371/journal.pone.0217434. eCollection 2019.

4.

[Follow-Up and Surveillance after Lung Cancer Treatment].

Tufman A, Duell T, Schneider C.

Zentralbl Chir. 2019 Feb;144(1):106-117. doi: 10.1055/s-0043-111766. Epub 2019 Feb 19. German.

PMID:
30780182
5.

Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib.

Kauffmann-Guerrero D, Kahnert K, Kumbrink J, Syunyaeva Z, Tufman A, Huber RM.

Clin Lung Cancer. 2019 Jan;20(1):59-62. doi: 10.1016/j.cllc.2018.09.009. Epub 2018 Sep 21. No abstract available.

PMID:
30341016
6.

Pretherapeutic Inflammation Predicts Febrile Neutropenia and Reduced Progression-Free Survival after First-Line Chemotherapy in SCLC.

Kauffmann-Guerrero D, Kahnert K, Syunyaeva Z, Tufman A, Huber RM.

Oncol Res Treat. 2018;41(9):506-512. doi: 10.1159/000488688. Epub 2018 Aug 8.

PMID:
30086542
7.

Less radiation, same quality: contrast-enhanced multi-detector computed tomography investigation of thoracic lymph nodes with one milli-sievert.

Mueller-Lisse UG, Marwitz L, Tufman A, Huber RM, Zimmermann HA, Walterham A, Wirth S, Paolini M.

Radiol Med. 2018 Nov;123(11):818-826. doi: 10.1007/s11547-018-0915-2. Epub 2018 Jun 30.

PMID:
29961228
8.

How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience.

Roengvoraphoj O, Eze C, Wijaya C, Dantes M, Taugner J, Tufman A, Huber RM, Bartenstein P, Belka C, Manapov F.

Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2103-2109. doi: 10.1007/s00259-018-4063-7. Epub 2018 Jun 6.

PMID:
29876620
9.

Dermal Filler Injections Mimic Tumor Activity during Immune Checkpoint Inhibition.

Syunyaeva Z, Kahnert K, Kauffmann-Guerrero D, Huber RM, Tufman A.

Respiration. 2018;95(5):362-363. doi: 10.1159/000487601. Epub 2018 Apr 5. No abstract available.

10.

Correction to: Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer.

Roengvoraphoj O, Wijaya C, Eze C, Li M, Dantes M, Taugner J, Tufman A, Huber RM, Belka C, Manapov F.

Strahlenther Onkol. 2018 Apr;194(4):363-364. doi: 10.1007/s00066-018-1290-6.

PMID:
29541791
11.

Rural versus urban differences in end-of-life care for lung cancer patients in Germany.

Walter J, Tufman A, Leidl R, Holle R, Schwarzkopf L.

Support Care Cancer. 2018 Jul;26(7):2275-2283. doi: 10.1007/s00520-018-4063-y. Epub 2018 Feb 4.

PMID:
29399722
12.

IGF-1-based screening reveals a low prevalence of acromegaly in patients with obstructive sleep apnea.

Heinrich DA, Reinholz C, Bauer M, Tufman A, Frohner R, Schopohl J, Bidlingmaier M, Kosilek RP, Reincke M, Schneider HJ.

Endocrine. 2018 May;60(2):317-322. doi: 10.1007/s12020-018-1538-z. Epub 2018 Jan 31.

PMID:
29388045
13.

NSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy.

Kauffmann-Guerrero D, Huber RM, Reu S, Tufman A, Mertsch P, Syunyaeva Z, Jung A, Kahnert K.

Respiration. 2018;95(3):169-176. doi: 10.1159/000484175. Epub 2017 Nov 30.

14.

Frequency and clinical relevance of EGFR mutations and EML4-ALK translocations in octogenarians with non-small cell lung cancer.

Tufman A, Kahnert K, Duell T, Kauffmann-Guerrero D, Milger K, Schneider C, Stump J, Syunyaeva Z, Huber RM, Reu S.

Onco Targets Ther. 2017 Oct 25;10:5179-5186. doi: 10.2147/OTT.S140472. eCollection 2017.

15.

Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer.

Roengvoraphoj O, Wijaya C, Eze C, Li M, Dantes M, Taugner J, Tufman A, Huber RM, Belka C, Manapov F.

Strahlenther Onkol. 2018 Feb;194(2):107-115. doi: 10.1007/s00066-017-1229-3. Epub 2017 Nov 7. Erratum in: Strahlenther Onkol. 2018 Mar 14;:.

PMID:
29116336
16.

Black and Blue.

Kauffmann-Guerrero D, Kahnert K, Pratschke S, Angstwurm M, Tufman A, Huber RM.

Respiration. 2017;94(5):465-466. doi: 10.1159/000479703. Epub 2017 Sep 7. No abstract available.

17.

Identification of a plasma miRNA biomarker signature for allergic asthma: A translational approach.

Milger K, Götschke J, Krause L, Nathan P, Alessandrini F, Tufman A, Fischer R, Bartel S, Theis FJ, Behr J, Dehmel S, Mueller NS, Kneidinger N, Krauss-Etschmann S.

Allergy. 2017 Dec;72(12):1962-1971. doi: 10.1111/all.13205. Epub 2017 Jun 19.

PMID:
28513859
18.

Cancer vaccination causes prolonged FDG accumulation in subcutaneous tissue.

Kahnert K, Kauffmann-Guerrero D, Tufman A, Borgmeier A, Huber RM, Berger F.

Nuklearmedizin. 2017 Apr 21. doi: 10.3413/Nukmed-0868-16-12. [Epub ahead of print] No abstract available.

PMID:
28429815
19.

Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine - a Phase I trial.

Guetz S, Tufman A, von Pawel J, Rittmeyer A, Borgmeier A, Ferré P, Edlich B, Huber RM.

Onco Targets Ther. 2017 Feb 21;10:1081-1089. doi: 10.2147/OTT.S122106. eCollection 2017.

20.

Clinical relevance of the M1b and M1c descriptors from the proposed TNM 8 classification of lung cancer.

Tufman A, Kahnert K, Kauffmann-Guerrero D, Manapov F, Milger K, Müller-Lisse U, Winter H, Huber RM, Schneider C.

Strahlenther Onkol. 2017 May;193(5):392-401. doi: 10.1007/s00066-017-1118-9. Epub 2017 Feb 28.

PMID:
28246699
21.

Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.

Brückl W, Tufman A, Huber RM.

Expert Rev Anticancer Ther. 2017 Feb;17(2):143-155. doi: 10.1080/14737140.2017.1266265. Epub 2016 Dec 12. Review.

PMID:
27898252
22.

A persistent pneumothorax? 5-year follow-up after diagnosis of Swyer-James-MacLeod syndrome.

Tufman A, Winter H, Kahnert K, Reu S, Müller-Lisse U, Huber RM.

Breathe (Sheff). 2016 Jun;12(2):e55-E58. doi: 10.1183/20734735.000316.

23.

Interleukin-22 is elevated in lavage from patients with lung cancer and other pulmonary diseases.

Tufman A, Huber RM, Völk S, Aigner F, Edelmann M, Gamarra F, Kiefl R, Kahnert K, Tian F, Boulesteix AL, Endres S, Kobold S.

BMC Cancer. 2016 Jul 7;16:409. doi: 10.1186/s12885-016-2471-2.

24.

Thoracic lymph node delineation at dose-reduced (1 mSv) dose-modulated contrast enhanced MDCT: a retrospective pilot study.

Paolini M, Wirth K, Tufman A, Reiser M, Huber RM, Mueller-Lisse UG.

Radiol Med. 2016 Aug;121(8):644-51. doi: 10.1007/s11547-016-0645-2. Epub 2016 May 6.

PMID:
27154525
25.

Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany.

Schremser K, Rogowski WH, Adler-Reichel S, Tufman AL, Huber RM, Stollenwerk B.

Pharmacoeconomics. 2015 Nov;33(11):1215-28. doi: 10.1007/s40273-015-0305-8.

PMID:
26081300
26.

Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.

Hoffknecht P, Tufman A, Wehler T, Pelzer T, Wiewrodt R, Schütz M, Serke M, Stöhlmacher-Williams J, Märten A, Maria Huber R, Dickgreber NJ; Afatinib Compassionate Use Consortium (ACUC).

J Thorac Oncol. 2015 Jan;10(1):156-63. doi: 10.1097/JTO.0000000000000380.

27.

Response to chemotherapy, reexposure to crizotinib and treatment with a novel ALK inhibitor in a patient with acquired crizotinib resistance.

Schrödl K, von Schilling C, Tufman A, Huber RM, Gamarra F.

Respiration. 2014;88(3):262-4. doi: 10.1159/000364949. Epub 2014 Aug 7.

28.

Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors.

Zimmermann GS, von Wulffen W, Huppmann P, Meis T, Ihle F, Geiseler J, Leuchte HH, Tufman A, Behr J, Neurohr C.

Respirology. 2014 Jul;19(5):700-6. doi: 10.1111/resp.12294. Epub 2014 Apr 3.

29.

Dehydroepiandrosterone modulates T-cell response after major abdominal surgery.

Pratschke S, von Dossow-Hanfstingl V, Dietz J, Schneider CP, Tufman A, Albertsmeier M, Winter H, Angele MK.

J Surg Res. 2014 Jun 1;189(1):117-25. doi: 10.1016/j.jss.2014.02.002. Epub 2014 Feb 12.

PMID:
24650456
30.

[Lung cancer].

Huber RM, Tufman A.

Dtsch Med Wochenschr. 2014 Mar;139(11):545-52; quiz 553-6. doi: 10.1055/s-0033-1349593. Epub 2014 Mar 4. Review. German. No abstract available.

PMID:
24595713
31.

Can microRNAs improve the management of lung cancer patients? A clinician's perspective.

Tufman A, Tian F, Huber RM.

Theranostics. 2013 Dec 5;3(12):953-63. doi: 10.7150/thno.6615. Review.

32.

Preselection based on clinical characteristics in German non-small-cell lung cancer patients screened for EML4-ALK translocation.

Tufman AL, Edelmann M, Gamarra F, Reu S, Borgmeier A, Schrödl K, Zauber R, Müller-Lisse U, Huber RM.

J Thorac Oncol. 2014 Jan;9(1):109-13. doi: 10.1097/JTO.0000000000000043.

33.

[Tumor conference II].

Tufman A, Schumann C, Huber RM, Eberhardt W, Flentje M, Haug A, Junker K, Pfluger T, Winter H.

Onkologie. 2013;36 Suppl 6:14-6. doi: 10.1159/000353715. Epub 2013 Aug 12. German. No abstract available.

34.

Interleukin-22 is frequently expressed in small- and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells.

Kobold S, Völk S, Clauditz T, Küpper NJ, Minner S, Tufman A, Düwell P, Lindner M, Koch I, Heidegger S, Rothenfuer S, Schnurr M, Huber RM, Wilczak W, Endres S.

J Thorac Oncol. 2013 Aug;8(8):1032-42. doi: 10.1097/JTO.0b013e31829923c8.

35.

Thoracoscopic resection of a giant midesophageal diverticulum.

Galata CL, Bruns CJ, Pratschke S, Tufman A, Mueller S, Winter H, Angele MK.

Ann Thorac Surg. 2012 Jul;94(1):293-5. doi: 10.1016/j.athoracsur.2011.12.087. Epub 2012 May 10.

PMID:
22579888
36.

Chronic progressive HIV-1 infection is associated with elevated levels of myeloid-derived suppressor cells.

Vollbrecht T, Stirner R, Tufman A, Roider J, Huber RM, Bogner JR, Lechner A, Bourquin C, Draenert R.

AIDS. 2012 Jul 31;26(12):F31-7. doi: 10.1097/QAD.0b013e328354b43f.

PMID:
22526518
37.

Tacrolimus preconditioning of rat liver allografts impacts glutathione homeostasis and early reperfusion injury.

Pratschke S, Bilzer M, Grützner U, Angele M, Tufman A, Jauch KW, Schauer RJ.

J Surg Res. 2012 Jul;176(1):309-16. doi: 10.1016/j.jss.2011.07.045. Epub 2011 Aug 25.

PMID:
21962731
38.

Organ-cocultures (COCs) for long term in vitro studies of lung cancer using 2-photon microscopy.

Edelmann M, Tufman A, Huber RM, Bergner A.

Technol Cancer Res Treat. 2011 Jun;10(3):275-9.

PMID:
21517134
39.

Influence of air pressure, humidity, solar radiation, temperature, and wind speed on ambulatory visits due to chronic obstructive pulmonary disease in Bavaria, Germany.

Ferrari U, Exner T, Wanka ER, Bergemann C, Meyer-Arnek J, Hildenbrand B, Tufman A, Heumann C, Huber RM, Bittner M, Fischer R.

Int J Biometeorol. 2012 Jan;56(1):137-43. doi: 10.1007/s00484-011-0405-x. Epub 2011 Feb 8.

PMID:
21301889
40.

GSH attenuates organ injury and improves function after transplantation of fatty livers.

Pratschke S, Angele MK, Grützner U, Tufman A, Bilzer M, Loehe F, Jauch KW, Schauer RJ.

Eur Surg Res. 2010;45(1):13-9. doi: 10.1159/000316643. Epub 2010 Aug 5.

PMID:
20689302
41.

Hypobaric hypoxia causes body weight reduction in obese subjects.

Lippl FJ, Neubauer S, Schipfer S, Lichter N, Tufman A, Otto B, Fischer R.

Obesity (Silver Spring). 2010 Apr;18(4):675-81. doi: 10.1038/oby.2009.509. Epub 2010 Feb 4.

42.

Endoplasmic reticulum Ca2+-homeostasis is altered in Small and non-small Cell Lung Cancer cell lines.

Bergner A, Kellner J, Tufman A, Huber RM.

J Exp Clin Cancer Res. 2009 Feb 24;28:25. doi: 10.1186/1756-9966-28-25.

43.

Biological markers in lung cancer: A clinician's perspective.

Tufman A, Huber RM.

Cancer Biomark. 2010;6(3-4):123-35. doi: 10.3233/CBM-2009-0124. Review.

PMID:
20660959
44.

Assessment of patient satisfaction with postoperative pain management after ambulatory gynaecologic laparoscopy.

Lovatsis D, José JB, Tufman A, Drutz HP, Murphy K.

J Obstet Gynaecol Can. 2007 Aug;29(8):664-7.

PMID:
17714620

Supplemental Content

Loading ...
Support Center